-

06:33:04 PM

JAZZ Stock News

JAZZ - Jazz Pharmaceuticals plc

01/19/23 7:45 AM

Nasdaq, NYSE : JAZZ, ZYME

clinical trial

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals plc and Zymeworks Inc. today announced tolerability and efficacy results, including the first overall survival data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with...

RHEA-AI

neutral

01/03/23 7:30 AM

Nasdaq : JAZZ

conferences

Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41 st Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company

RHEA-AI

neutral

12/21/22 7:30 AM

Nasdaq : JAZZ, ZYME

partnership

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to

RHEA-AI

very positive

12/05/22 8:00 AM

Nasdaq : JAZZ

Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies

Real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey presented at the 2022 American Epilepsy Society Annual Meeting expands evidence behind Epidiolex treatment in adult and pediatric patientsCaregivers of Lennox-Gastaut Syndrome and Dravet Syndrome

RHEA-AI

neutral

11/28/22 8:09 AM

Nasdaq : JAZZ

conferences

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ)

RHEA-AI

neutral

11/18/22 1:00 PM

Nasdaq : JAZZ

fda approval

Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the

RHEA-AI

very positive

11/14/22 9:00 AM

Nasdaq : JAZZ

STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING

Stand Up To Cancer ® (SU2C) announced today the launch of a new public service announcement (PSA) campaign in partnership with Jazz Pharmaceuticals plc. The PSA aims to raise awareness in Black and Hispanic communities about small cell lung cancer and

RHEA-AI

neutral

11/09/22 4:05 PM

Nasdaq : JAZZ

earnings

Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2022, and raised the mid-point of 2022 total revenue guidance. "Our execution across our business continues to chart a clear path to delivering on Vision 2025. We

RHEA-AI

positive

11/03/22 10:43 AM

Nasdaq : JAZZ

conferences

Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13

RHEA-AI

neutral

11/01/22 4:15 PM

Nasdaq : JAZZ

conferences

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences:Jefferies London Healthcare Conference on Tuesday, November 15, 2022The presentation is scheduled for 5:20 a.m. ET / 10:20

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

JAZZ Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.jazzpharma.com
Security nameJazz Pharmaceuticals plc
Issue typecs
SectorManufacturing
Sic code2834
Employees1940
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
StateWaterloo Exchange
CityFifth Floor
ZipWaterloo Road,Dublin 4
CountryIreland

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. Jazz Pharmaceuticals plc has a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. The company's focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic and solid tumors. They actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries.